Xinvento BC
Industry
- Pharmaceuticals
- Biotechnology
See more in Biomedtracker
Latest on Xinvento BC
In Vivo
• By Jo Shorthouse
Coming off the back of a challenging 2021 and 2022, many industry analysts cautiously forecast a bigger 2023, more deals, mergers and IPOs. While this has not happened, bar a few delicious morsels suc
Scrip
• By Joseph Haas
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre